{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T00:25:47Z","timestamp":1794097547253,"version":"4.8.0"},"reference-count":52,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6S","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have expanded from metabolic therapeutics to agents with broad effects on inflammation, tissue repair, cutaneous and adipose biology, and aging-related pathways. Clinicians increasingly encounter cutaneous manifestations and aesthetic sequelae with important implications for dermatologic counseling and multidisciplinary care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To review current evidence regarding GLP-1RA effects on skin biology, inflammatory dermatoses, wound healing, cutaneous adverse events, and aesthetic aging.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>A narrative review of clinical, translational, and mechanistic literature was performed, emphasizing psoriasis, hidradenitis suppurativa, wound repair, skin hypersensitivity reactions, autoimmune blistering disease, and facial volume loss associated with pharmacologic weight reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>GLP-1RAs are hypothesized to improve inflammatory skin conditions and wound repair through anti-inflammatory, immunometabolic, and proreparative pathways. Yet, their use may also be associated with injection-site reactions, hypersensitivity eruptions, rare autoimmune blistering disorders, and clinically significant facial deflation and skin laxity. Current evidence is strongest for mechanistic plausibility and observational clinical signals, whereas dermatology-specific randomized trials remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>GLP-1RAs exert bidirectional effects on cutaneous biology. Recognition of both therapeutic opportunities and potential aesthetic or adverse sequelae is important, with patient counseling ideally occurring within a multidisciplinary framework that integrates metabolic benefits with skin health and appearance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/dss.0000000000005187","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T09:00:47Z","timestamp":1780045247000},"page":"S45-S54","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Cutaneous Biology: Implications for Skin Disease and Longevity"],"prefix":"10.1097","volume":"52","author":[{"given":"Krishna","family":"Vyas","sequence":"first","affiliation":[{"name":"Private Practice, New York, New York;"},{"name":"Department of Plastic Surgery, Manhattan Eye, Ear and Throat Hospital and Lenox Hill Hospital, New York, New York"},{"name":"Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Mayo Clinic Department of Dermatology, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gopinath","sequence":"additional","affiliation":[{"name":"Mayo Clinic Department of Dermatology, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara","family":"Dacso","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy B.","family":"Green","sequence":"additional","affiliation":[{"name":"Skin Associates of South Florida, Skin Research Institute, Coral Gables, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saranya","family":"Wyles","sequence":"additional","affiliation":[{"name":"Mayo Clinic Department of Dermatology, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260730","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00266-019-01397-3","article-title":"Profile of adipose-derived stem cells in obese and lean environments","volume":"43","author":"Vyas","year":"2019","journal-title":"Aesthet Plast Surg"},{"key":"R2-20260730","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","article-title":"Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits","volume":"407","author":"Nauck","year":"2026","journal-title":"Lancet"},{"key":"R3-20260730","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"R4-20260730","doi-asserted-by":"crossref","first-page":"NP809","DOI":"10.1093\/asj\/sjae132","article-title":"Decoding the implications of glucagon-like peptide-1 receptor agonists on accelerated facial and skin aging","volume":"44","author":"Ridha","year":"2024","journal-title":"Aesthet Surg J"},{"key":"R5-20260730","doi-asserted-by":"crossref","first-page":"156547","DOI":"10.1016\/j.metabol.2026.156547","article-title":"The multifaceted role of GLP-1 in metabolic disorders, chronic inflammation, and aging: mechanisms and therapeutic potential","volume":"178","author":"Li","year":"2026","journal-title":"Metabolism"},{"key":"R6-20260730","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/exd.12081","article-title":"Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques","volume":"22","author":"Faurschou","year":"2013","journal-title":"Exp Dermatol"},{"key":"R7-20260730","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.yexmp.2019.01.014","article-title":"GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK","volume":"107","author":"Yang","year":"2019","journal-title":"Exp Mol Pathol"},{"key":"R8-20260730","doi-asserted-by":"crossref","first-page":"106320","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"R9-20260730","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/s12020-025-04293-w","article-title":"GLP-1RA and the possible skin aging","volume":"89","author":"Paschou","year":"2025","journal-title":"Endocrine"},{"key":"R10-20260730","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/jdv.20694","article-title":"The effects of GLP-1RA on inflammatory skin diseases: a comprehensive review","volume":"39","author":"Paschou","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R11-20260730","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s11154-023-09825-1","article-title":"Beyond glycemia: comparing tirzepatide to GLP-1 analogues","volume":"24","author":"Andraos","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"key":"R12-20260730","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis","volume":"65","author":"Karagiannis","year":"2022","journal-title":"Diabetologia"},{"key":"R13-20260730","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1007\/s40618-024-02441-z","article-title":"The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"47","author":"Caruso","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"R14-20260730","doi-asserted-by":"crossref","first-page":"829e","DOI":"10.1097\/PRS.0000000000010767","article-title":"Pharmacologic and other noninvasive treatments of the aging face: a review of the current evidence","volume":"154","author":"Bustos","year":"2024","journal-title":"Plast Reconstr Surg"},{"key":"R15-20260730","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.mce.2014.12.021","article-title":"Effect of liraglutide on proliferation and differentiation of human adipose stem cells","volume":"402","author":"Cantini","year":"2015","journal-title":"Mol Cell Endocrinol"},{"key":"R16-20260730","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1111\/bph.13481","article-title":"Effects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes","volume":"173","author":"El Bekay","year":"2016","journal-title":"Br J Pharmacol"},{"key":"R17-20260730","first-page":"89","article-title":"Effects of GLP-1 receptor agonists on human mesenchymal stem cells: a systematic review","volume":"15","author":"Chen","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"R18-20260730","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/exd.12941","article-title":"Dermal adipocytes and hair cycling: is spatial heterogeneity a characteristic feature of the dermal adipose tissue depot?","volume":"25","author":"Kruglikov","year":"2016","journal-title":"Exp Dermatol"},{"key":"R19-20260730","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr"},{"key":"R20-20260730","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/MED.0000000000000934","article-title":"Effect of GLP-1 receptor agonists on body composition","volume":"32","author":"Bhandarkar","year":"2025","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R21-20260730","first-page":"CD015092","article-title":"Semaglutide for adults living with obesity","volume":"10","author":"Bracchiglione","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"R22-20260730","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jamainternmed.2025.1794","article-title":"Integrating diet and physical activity when prescribing GLP-1s\u2014lifestyle factors remain crucial","volume":"185","author":"Mehrtash","year":"2025","journal-title":"JAMA Intern Med"},{"key":"R23-20260730","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1007\/s00228-025-03898-4","article-title":"GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management\u2014current evidence and future outlook","volume":"81","author":"Atiquzzaman","year":"2025","journal-title":"Eur J Clin Pharmacol"},{"key":"R24-20260730","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00011-025-02140-2","article-title":"The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review","volume":"74","author":"Buonanno","year":"2025","journal-title":"Inflamm Res"},{"key":"R25-20260730","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.diabres.2019.03.002","article-title":"Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: a prospective cohort study","volume":"150","author":"Xu","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"R26-20260730","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41584-025-01302-0","article-title":"Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions","volume":"21","author":"Karacabeyli","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"R27-20260730","first-page":"103512","article-title":"Impact of GLP-1 analogues on immune-mediated inflammatory diseases: a systematic review","volume":"24","author":"Birda","year":"2025","journal-title":"Autoimmun Rev"},{"issue":"(Suppl 3)","key":"R28-20260730","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3899\/jrheum.2025-0531","article-title":"What clinicians need to know about glucagon-like peptide 1 agonists","volume":"52","author":"da Silva","year":"2025","journal-title":"J Rheumatol"},{"key":"R29-20260730","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jamadermatol.2025.2723","article-title":"Glucagon-like peptide-1 receptor agonists in hidradenitis suppurativa","volume":"161","author":"Gouvrion","year":"2025","journal-title":"JAMA Dermatol"},{"key":"R30-20260730","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1016\/j.jid.2025.08.045","article-title":"GLP-1 receptor agonists as emerging modulators of inflammation and angiogenesis in chronic cutaneous wound healing","volume":"145","author":"Ghebrehiwet-Kuflom","year":"2025","journal-title":"J Invest Dermatol"},{"key":"R31-20260730","doi-asserted-by":"crossref","first-page":"e2405987","DOI":"10.1002\/advs.202405987","article-title":"Liraglutide promotes diabetic wound healing via Myo1c\/Dock5","volume":"11","author":"Zhang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"R32-20260730","doi-asserted-by":"crossref","first-page":"171366","DOI":"10.1016\/j.peptides.2025.171366","article-title":"Dulaglutide accelerates diabetic wound healing by suppressing Nrf2-dependent ferroptosis in diabetic mice","volume":"185","author":"Xi","year":"2025","journal-title":"Peptides"},{"key":"R33-20260730","doi-asserted-by":"crossref","first-page":"114050","DOI":"10.1016\/j.intimp.2025.114050","article-title":"Pro-healing impact of liraglutide on skin wounds in normoglycemic mice","volume":"147","author":"Yue","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"R34-20260730","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.diabres.2018.10.013","article-title":"Glucagon-like peptide-1 analogue liraglutide facilitates wound healing by activating PI3K\/Akt pathway in keratinocytes","volume":"146","author":"Nagae","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"R35-20260730","doi-asserted-by":"crossref","DOI":"10.1016\/j.avsg.2026.03.023","article-title":"GLP-1 receptor agonist use is associated with venous ulcer healing and fewer wound infections","author":"Go","year":"2026","journal-title":"Ann Vasc Surg"},{"key":"R36-20260730","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2025.12.116","article-title":"JAAD CME part 2: clinical evidence and safety considerations for GLP-1 receptor agonists in dermatology","author":"Narla","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"R37-20260730","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamadermatol.2015.4499","article-title":"Insulin resistance and metabolic syndrome in young men with acne","volume":"152","author":"Nagpal","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R38-20260730","doi-asserted-by":"crossref","first-page":"1252972","DOI":"10.3389\/fphys.2023.1252972","article-title":"Insulin and the sebaceous gland function","volume":"14","author":"Okoro","year":"2023","journal-title":"Front Physiol"},{"key":"R39-20260730","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1684\/ejd.2016.2748","article-title":"The relationship between rosacea and insulin resistance and metabolic syndrome","volume":"26","author":"Akin Belli","year":"2016","journal-title":"Eur J Dermatol"},{"key":"R40-20260730","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s00403-024-02969-3","article-title":"Rare cutaneous adverse reactions associated with GLP-1 agonists: a review of the published literature","volume":"316","author":"Salazar","year":"2024","journal-title":"Arch Dermatol Res"},{"key":"R41-20260730","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1111\/dom.70382","article-title":"Injection-site and dermatologic reactions associated with glucagon-like peptide-1 receptor agonists: insights from meta-analysis of randomised controlled trials and real-world evidence","volume":"28","author":"Taj","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"R42-20260730","doi-asserted-by":"crossref","first-page":"11","DOI":"10.36849\/JDD.9448","article-title":"Cutaneous adverse events associated with GLP-1 receptor agonists: a FAERS database analysis from 2018-2024","volume":"25","author":"Fat","year":"2026","journal-title":"J Drugs Dermatol"},{"key":"R43-20260730","doi-asserted-by":"crossref","first-page":"413","DOI":"10.36849\/JDD.6550","article-title":"Dermal hypersensitivity reaction to semaglutide: two case reports","volume":"22","author":"Ouellette","year":"2023","journal-title":"J Drugs Dermatol"},{"key":"R44-20260730","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1001\/jamadermatol.2018.4556","article-title":"Association of dipeptidyl peptidase 4 inhibitor use with risk of bullous pemphigoid in patients with diabetes","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol"},{"key":"R45-20260730","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.2337\/dc19-0409","article-title":"Dipeptidyl peptidase 4 inhibitors and the risk of bullous pemphigoid among patients with type 2 diabetes","volume":"42","author":"Douros","year":"2019","journal-title":"Diabetes Care"},{"key":"R46-20260730","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.7150\/ijms.55421","article-title":"Bullous pemphigoid and diabetes medications: a disproportionality analysis based on the FDA Adverse Event Reporting System","volume":"18","author":"Huang","year":"2021","journal-title":"Int J Med Sci"},{"key":"R47-20260730","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.jaad.2018.05.030","article-title":"Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: a Finnish nationwide case-control study","volume":"79","author":"Varpuluoma","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"R48-20260730","article-title":"Disruptions in aesthetic medicine: a global analysis of GLP-1 agonists using punctuated equilibrium framework","author":"Rahman","year":"2025","journal-title":"Plast Reconstr Surg"},{"key":"R49-20260730","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/oby.24321","article-title":"Effects of obesity-associated plasma markers on adipose stem cell function and epigenetic regulation","volume":"33","author":"Bispo","year":"2025","journal-title":"Obesity (Silver Spring)"},{"key":"R50-20260730","doi-asserted-by":"crossref","DOI":"10.1097\/SCS.0000000000012582","article-title":"Losing weight and gaining wrinkles: the impact of weight loss drugs on facial aesthetics","author":"Bari\u015fkan","year":"2026","journal-title":"J Craniofac Surg"},{"key":"R51-20260730","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/asj\/sjaf240","article-title":"A multicenter, open-label study of combined poly-L-lactic acid and hyaluronic midface filler regimen enhances facial harmony and skin quality in GLP-1 medication users","volume":"46","author":"Lorenc","year":"2026","journal-title":"Aesthet Surg J"},{"key":"R52-20260730","doi-asserted-by":"crossref","first-page":"e13818","DOI":"10.1111\/acel.13818","article-title":"Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: current and future potentials","volume":"22","author":"Kreiner","year":"2023","journal-title":"Aging Cell"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T04:02:47Z","timestamp":1785384167000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/DSS.0000000000005187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":52,"journal-issue":{"issue":"6S","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000005187","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}